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ABSTRACT 
 
 
 Phytochemical studies of Artocarpus lowii King, A. scortechinii King and A. 
teysmanii Miq. have resulted in the isolation of four new compounds and eight known 
compounds. Three new compounds have been successfully isolated from A. lowii King, 
i.e 2′,4′-dihydroxy-4-methoxy-3′-prenyldihydrochalcone, 2′,3,4′,4-tetrahydroxy-3′-
prenylchalcone and 2-hydroxyparatocarpin C. Three known compounds were identified 
as cycloheterophyllin, 2′,4′,4-trihydroxy-3′-prenylchalcone and 4-hydroxylonchocarpin. 
A new compound was isolated from A. scortechinii King and was identified as 2′,4′,5′,5-
tetrahydroxy-3-geranyl-7,8-(2,2-dimethyl-6H-pyrano)-6-prenylflavone together with 
three known compounds, i.e artonin E, artobiloxanthone and lupeol 3-acetate. Four 
known compounds were isolated from A. teysmanii Miq., which were identified as 
artonin E, artobiloxanthone, artonol B and cycloartobiloxanthone. The structures of all 
compounds were established based on spectral studies using nuclear magnetic resonance 
spectroscopy, mass spectrometry, infrared spectroscopy and ultraviolet spectroscopy. The 
biological studies on the crude extracts and pure compounds of these three species 
showed that several pure compounds have significant biological activity especially in the 
platelet aggregation assays. Cycloheterophyllin, artonin E, isobavachalcone and 2′,4′-
dihydroxy-4-methoxy-3′-prenyldihydrochalcone totally inhibited ADP-induced platelet 
aggregation compared to standard aspirin which suppressed only 31.6% of the platelet 
aggregation.  
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ABSTRAK 
 
 
 Kajian fitokimia ke atas Artocarpus lowii King, A. scortechinii King dan A. 
teysmanii Miq. berjaya menemukan empat sebatian baru dan lapan sebatian yang 
diketahui. Tiga sebatian baru ditemui daripada A. lowii King dikenalpasti sebagai 2′,4′-
dihidroksi-4-metoksi-3′-prenildihidrokalkon,  2′,3,4′,4-tetrahidroksi-3′-prenil-kalkon dan  
2-hidroksiparatokarpin C. Tiga sebatian lain dikenalpasti sebagai sikloheterofillin, 2′,4′,4-
trihidroksi-3′-prenilkalkon dan 4-hidroksilonchokarpin. Satu sebatian baru telah berjaya 
diasingkan daripada A. scortechinii King dan dikenalpasti sebagai 2′,4′,5′,5-tetrahidroksi-
3-geranil-7,8-(2,2-dimetil-6H-pirano)-6-prenilflavon bersama-sama tiga sebatian 
diketahui iaitu artonin E, artobiloxanton dan lupeol 3-asetat. Empat sebatian berjaya 
diasingkan daripada A. teysmanii Miq. dan dikenalpasti sebagai artonin E, artobiloxanton, 
artonol B dan sikloartobiloxanton. Struktur kesemua sebatian dikenalpasti berdasarkan 
kepada kajian spektra dengan menggunakan spektroskopi resonan magnetik nukleus, 
spektrometri jisim, spektroskopi infra merah dan spektroskopi ultralembayung. Kajian 
aktiviti biologi ke atas ekstrak mentah dan sebatian tulen daripada ketiga-tiga spesies 
Artocarpus ini mendapati beberapa sebatian menunjukkan aktiviti biologi yang signifikan 
terutamanya di dalam asai aggregasi platelet. Sikloheterofillin, artonin E, isobavakalkon 
dan 2′,4′-dihidroksi-4-metoksi-3′-prenildihidrokalkon merencat 100% aggregasi platelet 
yang dirangsang oleh ADP, berbanding dengan aspirin yang hanya mampu merencat 
sebanyak 31.6% sahaja. 
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1.1 INTRODUCTION 
 
Artocarpus is the most commonly encountered genus, representatives of the 
Moraceae in the lowland forest of the tropical Southeast Asia, apart from Ficus. There are 
47 species of Artocarpus in which only 20 species including the cultivated plants could 
be found in Malaysia. This genus is known world wide for its edible fruits like the 
jackfruit, A. heterophyllus locally known as ‘nangka’, bread fruit, A. communis (‘sukun’) 
and ‘cempedak’, A. integer. These species are widely cultivated in Malaysia as villagers 
and traders commercially sell their fruits in local market. The lightwood known locally as 
‘terap’ and the medium hardwood known as ‘keledang’ constitute valuable timber 
resources [1, 2]. Some of Malaysian Artocarpus species are rare. Most of these species 
have never been chemically and biologically investigated including A. anisophyllus, A. 
bracteata, A. fulvicortex. A. hispidus, A. kemando, A. lowii, A. nitidus, and A. 
odoratissima [1].  
 
Artocarpus species have been studied quite thoroughly, chemically or biologically 
by few groups of researchers from Indonesia, Japan, and Taiwan. Most of the plants 
studied were collected from the rain forest of Indonesia. Some studies cover Artocarpus 
species of Taiwan, Carribean and Thailand. Several new and interesting compounds have 
been isolated, characterized and evaluated for their biological activities. Artocarpus 
plants have also been used as traditional medicine especially in Indonesia against 
inflammation, malarial fever and stomachache.  
 
 
1.2 BIOLOGICALLY ACTIVE PHYTOCHEMICALS FROM SEVERAL 
ARTOCARPUS SPECIES 
 
Artocarpus species are noted as an abundant source of phenolic constituents. 
These constituents can be classified into isoprenylflavonoids, stilbenoid and 2-
arylbenzofuran derivatives, phenolic compounds with oxepine ring and natural Diels-
Alder type adducts. Biological studies on the phytochemicals isolated from these plants 
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showed some interesting findings which some how justified the usage of Artocarpus 
plants in traditional practices.  
 
 Artonin E (1) and B (2) which were isolated from A. communis showed stronger 
activity against cancer cells, mouse L-1210 and colon 38 compared to the critical drug, 
theafulvin (3). Artonin E (1) also exhibited the most potent inhibition on arachidonate 5-
lipoxygenase with IC50 value of 0.36 µM [3, 4]. Artonin E (1) was also expected to be an 
anti-tumor promoter based on the similarity of the structure with morusin (4) which was 
isolated from the root bark of Morus alba L.. The latter compound had been reported as 
an anti-tumor promoter in a two-stage carcinogenesis experiment with teleocidin [5, 6]. 
Both compounds have an isoprenoid moiety at the C-3 position. The difference is in the B 
ring where morusin (4) has a structure bearing a 2′,4′-dioxygenated pattern while artonin 
E (1) has a structure bearing a 2′,4′,5′-trioxygenated pattern. Thus, the inhibitory effect of 
the Artocarpus flavonoids on tumor-necrocis factor-α (TNF-α) release stimulated by 
okadaic acid using BALB/3T3 cells has been examined [7, 8]. All the tested compounds 
inhibited the TNF-α release stimulated by okadaic acid at suitable lower concentration. 
Artonin E (1) was found to be the most potent inhibitor. Heterophyllin (5) and 
artobiloxanthone (6) inhibited stronger than cycloheterophyllin (7), 
cycloartobiloxanthone (8), and morusin (4). The compounds which exhibited strong 
activity have three hydroxyl groups in the B ring. This characteristic feature might be one 
of the important factors for their biological activity. 
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 The cytotoxicity of prenylflavonoids isolated from the Formosan A. communis 
against human hepatoma PLC/PRF/5 and KB cells in vitro had also been reported [9]. 
Artomunoxanthotrione epoxide (9), cyclocommunol (10), and cyclocommunin (11) 
showed cytotoxic activities against both cells with ED50 values not more than 2.5 µg/mL. 
Cyclocommunol (10), and cyclocommunin (11) were also reported to have antiplatelet 
actions on collagen-induced and arachidonic acid-induced platelet aggregation with little 
or no effect on PAF-induced platelet aggregation [10]. The antiplatelet activities of 
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prenylated flavonoids isolated from A. heterophyllus was also reported where 
cycloheterophyllin (7) showed inhibition of arachidonic acid-induced platelet aggregation 
with IC50 value of 10.9 µM [11]. The antibacterial activity of A. heterophyllus against 
Gram-positive and Gram-negative bacteria has also been studied. The extract of A. 
heterophyllus showed a broad spectrum of antibacterial activity [12]. The extract also 
showed activity against cariogenic bacteria. The extract inhibited the growth of primary 
cariogenic bacteria at concentration of 3.11-12.5 µg/mL and also exhibited the growth 
inhibitory effects on plague-forming Streptococci. This finding showed that 
phytochemicals from A. heterophyllus would be potent compounds for the prevention of 
dental caries [13].  
 
   (9)      (10) 
 
 
      (11) 
 
 
In this study, the crude extracts and phytochemicals from Malaysian species i.e. 
Artocarpus lowii, A. scortechinii and A. teysmanii were tested for their platelet activating 
factor (PAF) receptor binding inhibitory and antiplatelet aggregation activity.  
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1.3 EXPERIMENTAL 
1.3.1 Platelet Activating Factor (PAF) Receptor Binding Activity 
 
The assay was carried out according to the modified method of Valone et al. [14]. 
The pure compounds were each dissolved in DMSO and ethanol (1:1). The stock 
solutions were diluted with normal saline to give final concentrations of 200, 100, 50, 20 
and 10 µg/mL. The final concentrations of the sample in the reaction mixtures were either 
18.2, 9.1, 4.5, 1.8 or 0.9 µg/mL. The final concentration of DMSO in the reaction mixture 
was fixed at 0.2% to avoid interference with the receptor binding studies. The reaction 
mixture with saline and 0.2% DMSO in saline was used as a control.  
 
Six volumes of blood were collected from the rabbit (New Zealand White) 
marginal ear vein directly into 1 volume of ACD solution (0.15 M trisodium citrate, 
0.075 M citric acid, pH 5.2). The blood was centrifuged at 270 × g for 10 min at room 
temperature, and the top platelet-rich plasma was removed carefully. The latter was 
further centrifuged at 500 × g for 15 min. The platelet pellets were washed twice by 
centrifugation at 500 × g (15 min) in buffer A (20% ACD solution, 60% K2HPO4 buffer, 
20% sodium citrate, pH 6.8) followed once at 150 × g (10 min) in buffer B (50 mL 
K2HPO4, 0.1 g bovine serum albumin, pH 7.0). The final platelet concentration was 
adjusted to 3 × 108 platelets/mL.  
 
The reaction mixture consisted of 200 µL of washed rabbit platelet suspension, 25 
µL of 3H-PAF (2.0 nM) with or without unlabelled PAF (2.0 nM) and 25 µL of sample or 
control solution. Cedrol, a known PAF receptor antagonist, was used as a standard in the 
bioassay. The reaction mixture was incubated at room temperature for 1 hour. The free 
and bound ligands were separated by filtration technique using Whatman GF/C glass 
fibre filters. The radioactivity was measured by scintillation counting. The difference 
between the total radioactivities of bound 3H-PAF in the absence and in the presence of 
excess unlabelled PAF is defined as the specific binding of the radiolabelled ligand. The 
IC50 values of the samples were obtained from at least three determinations. Percentage 
inhibition effect of the sample was obtained by the following equation: 
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where Sc = specific binding of control; Ss = specific binding of sample; Tc = total 
binding of control; Ts = total binding of sample; Nc = nonspecific binding of control; Ns 
= nonspecific binding of sample 
 
 
 
1.3.2 Platelet Aggregation Assay 
  
 The platelet aggregation assay was conducted using electrical impedance method 
[21]. Whole blood (1 mL) diluted with phosphate-buffered saline (1:1 ratio) was 
incubated with samples (5 µL, in DMSO) at 37°C for 2 min, after which collagen (2 
µg/mL), ADP (10 µM), and AA (0.5 mM) was added to initiate aggregation. The platelet 
aggregation was measure by a Whole Blood Lumi-Aggregometer using an electrical 
impedance method. The mean percentages of aggregation in whole blood was determined 
at 5 min as the increase in impedance across a pair of electrodes placed in the blood 
sample by comparison to that of a control group impedance. To eliminate the effect of the 
solvent on the aggregation, blood with 0.5% DMSO was used as the control. Each sample 
was measured in triplicate. The percentage inhibition of platelet aggregation was 
calculated as follows: 
 
% Inhibition  = [1-(aggregation of sample/aggregation of control)]  × 100 
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1.4 RESULTS AND DISCUSSION 
1.4.1 Platelet Activating Factor (PAF) Receptor Binding Activity 
 
The PAF assay was conducted based on Valone et al. [14]. Platelet activating 
factor (PAF) or 1-alkyl-2-acetyl-glycero-3-phosphocholine is a pair of phospholipids 
produced by proinflammatory cells such as endothelia cells, platelets, macrophages, and 
monocytes [15]. It involves several pharmacological actions, such as the induction of 
platelet and neutrophil aggregation, bronchoconstriction, hypotension, and increased 
vascular permeability. PAF may also be involved in a variety of pathophysiological 
conditions, including arterial thrombosis, acute inflammation, endotoxic shock, acute 
allergic disease, and early pregnancy [16-18]. Therefore, specific antagonists of PAF that 
inhibit the specific binding to the receptors may be useful therapeutic agents and have 
been extensively sought from natural sources or produced synthetically. Several natural 
and synthetic antagonists with diverse chemical structures have been discovered [19]. 
This suggests that the receptor molecule may accommodate a wide variety of ligand 
structures, hence, there is still the possibility of finding new PAF antagonists especially 
from natural products [20].  
 
 Eleven compounds were investigated for their PAF receptor binding inhibitory 
effects using rabbit platelets. Cedrol (12), a known PAF receptor antagonist was used as a 
standard. Table 1.1 shows the percentage inhibitory effects of the compounds at 
concentration of 18.2 µg/mL. Compound that gives more than 55% inhibitory effect is 
considered active. In this assay, all compounds exhibited low effects except for artonin E, 
cycloheterophyllin, and isobavachalcone which showed moderate inhibitory effects 
compared to cedrol with values of 42%, 51%, and 49% respectively. These results 
indicate that most of the tested compounds were weak PAF receptor antagonists.  
 
(12) 
OH
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Table 1.1: Inhibitory Effects of Compounds of Artocarpus Species on PAF           
Receptor Binding to Rabbit Plateletsa 
Compounds Inhibition (%) 
Cycloheterophyllin  42 
Artonin E  51 
Artobiloxanthone  19 
Cycloartobiloxanthone  13 
Artonol B  3 
Isobavachalcone  49 
4-hydroxylonchocarpin  34 
2′,4′-dihydroxy-4-methoxy-3′-prenyldihydrochalcone  32 
Cycloheterophyllin diacetate  30 
Lupeol 3-acetate  5 
Artonin E tetraacetate  29 
Cedrol (12)b 70 
         a Concentration of sample in reaction mixture = 18.2 µg/mL 
         b Standard antagonist 
 
 
1.4.2 Platelet Aggregation Activity 
 
 Seven compounds isolated from Artocarpus lowii, A. scortechinii and A. 
teysmanii and two of their derivatives were evaluated for their ability to inhibit platelet 
aggregation of human whole blood induced by collagen, adenosine diphosphate (ADP) 
and arachidonic acid (AA) in vitro using an electrical impedance method [21]. 
Acetylsalicylic acid (aspirin) was used as a reference. Aspirin is an antiplatelet agent that 
inhibits platelet cyclooxygenase-1 (COX-1) and, as a consequence, prevents the 
formation of the pro-aggregatory substance, thromboxane A2 (TXA2) [22]. The whole 
blood with 0.5% DMSO was used as the control. This is to eliminate the effect of the 
solvent on the aggregation. Collagen, ADP and AA was the agonists that triggered 
platelet aggregation in the pathogenesis of several diseases including atherosclerosis and 
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cardiovascular malfunction [23, 24]. In this study, the percentage of the inhibitory effects 
of each tested compound and aspirin on platelet aggregation induced by 2 µg/mL 
collagen, 10 µM ADP and 0.5 mM AA were sought. The results were summarized in 
Table 1.2.  
 
The results showed that cycloheterophyllin, artonin E, isobavachalcone, and 2′,4′-
dihydroxy-4-methoxy-3′-prenyldihydrochalcone totally inhibited ADP-induced platelet 
aggregation (100.0%) compared to aspirin which suppressed only 31.6% of the platelet 
aggregation. Cycloartobiloxanthone and artonin tetraacetate also showed promising 
results by 89.5% inhibition each. Further, cycloheterophyllin and artonin E showed 
moderate effect on AA-induced aggregation by 66.7% and 58.3%, respectively, while 
aspirin showed 100.0% inhibition. For collagen-induced aggregation, only artonin E and 
artonin tetraacetate gave significant results with inhibition values of 55.0% and 45.0% 
respectively compared to aspirin which gave 45.0% inhibition.  
 
 In conclusion, all compounds inhibited platelet aggregation induced by ADP more 
than the reference, aspirin except for artobiloxanthone and cycloheterophyllin diacetate. 
Only artonin E and its derivatives showed significant inhibition on platelet aggregation 
induced by collagen. All compounds showed weak activity on platelet aggregation 
induced by AA compared to aspirin.  
 
 
 
 
 
 
 
 
 
 
  
10
Table  1.2 :  Percentage  Inhibition  of  Compounds  (100 µg/mL)  From   Artocarpus       
lowii, A. scortechinii and A. teysmanii, Two Derivatives and Aspirin (25 
µg/mL) on Platelet Aggregation of Human Whole Blood 
 
Inhibition (%) 
Compound 
Collagen 
(2 µg/mL) 
ADP 
(10 µM) 
AA 
(0.5 mM) 
Cycloheterophyllin  30.0 ± 1.41 100.0 ± 0.0 66.7 ± 0.0 
Artonin E  55.0 ± 0.71 100.0 ± 0.0 19.1 ± 0.71 
Artobiloxanthone  0.0 ± 0.0 15.8 ± 1.41 4.8 ± 0.0 
Cycloartobiloxanthone  0.0 ± 0.0 89.5 ± 0.0  4.8 ± 0.0 
Artonol B  30.0 ± 1.41 36.8 ± 0.0  14.3 ± 1.41 
Isobavachalcone  40.0 ± 1.0 100.0 ± 0.0 38.1 ± 0.71 
2′,4′-dihydroxy-4-methoxy-3′-
prenyldihydrochalcone  
30.0 ± 0.0 100.0 ± 0.0 58.3 ± 0.71 
Cycloheterophyllin diacetate  20.0 ± 0.0 0.0 ± 0.0 19.1 ± 0.71 
Artonin E tetraacetate  45.0 ± 0.71 89.5 ± 1.41 14.3 ± 0.0 
Aspirin 45.0 ± 0.71 31.6 ± 1.0 100.0 ± 0.0 
 
 
1.5 CONCLUSION 
 
The results, especially in the platelet aggregation study revealed that 
phytochemicals isolated from Malaysian Artocarpus plants can be further developed to 
be used as antiallergy, antiasthmetic and antiinflammatory drugs. 
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